Numinus Explores Group Therapy in MDMA Study

Numinus Wellness (TSE:NUMI) has released an update.

Numinus Wellness Inc. has been greenlit by Health Canada to conduct a groundbreaking study on MDMA-assisted psychotherapy within a group setting, focusing on the therapy’s delivery and the optimal number of therapists required. The clinical trial also offers a unique training opportunity for practitioners to gain firsthand experience and insights into the therapeutic use of MDMA. This research contributes to the evolving understanding and potential integration of psychedelic-assisted treatments in mainstream mental health care.

For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.